CHOEP + High Dose Therapy + Auto SCT for T-Cell Lymphoma

Status: Recruiting
Phase: Phase 2
Diagnosis: Hematopoietic Stem Cell Transplant
NCT ID: NCT01746173 (View complete trial on ClinicalTrials.gov)
DFCI Protocol ID: 12-388

 

This is a phase II study of CHOEP induction chemotherapy followed by autologous stem cell transplant using gemcitabine/busulfan/melphalan conditioning in patients with newly diagnosed systemic T-cell non-Hodgkin lymphoma.

 

Conducting Institutions:
Dana-Farber Cancer Institute, Brigham and Women's Hospital, Massachusetts General Hospital, Beth-Israel Deaconess Medical Center

Overall PI:
Philippe Armand, MD, Dana-Farber Cancer Institute

Site-responsible Investigators:

Contacts:
Dana-Farber Cancer Institute: Mildred Pasek, mpasek@partners.org

Eligibility Criteria

Inclusion Criteria: - Diagnosis of T-Cell lymphoma with mandatory pathologic review at Brigham and Women's Hospital or Massachusetts General Hospital - Measurable disease - Candidate for Autologous Stem Cell Transplant Exclusion Criteria: - Prior anti-lymphoma chemotherapy (except steroids/radiotherapy for urgent palliation, one prior cycle of CHOP or up to 2 prior cycles of CHOEP) - Pregnant or breastfeeding - Alk-positive ACL - Significant neuropathy precluding vincristine administration - Known hypersensitivity to any of the agents used in the treatment - Uncontrolled intercurrent illness - Receiving other investigational agents - History of a different malignancy except if disease free for at least 5 years or have cervical cancer in situ or basal cell/squamous cell carcinoma of the skin - HIV positive on anti-retroviral therapy
  • Email
  • Print
  • Share
  • Text
Highlight Glossary Terms